[A21-79] Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 19.11.2021
Project no.:
A21-79
Commission:
Commission awarded on 01.07.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Treatment of adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)
Hint of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A18-33 | Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-54 | Bosutinib (pretreated chronic myelogenous leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G13-01 | Bosutinib - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A21-134 | Bosutinib (chronic myelogenous leukaemia) - Addendum to Commission A21-79 | Commission completed |
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.